The latest issue of Pharma Technology Focus is out now. Read it for free on all devices.

Pharmacovigilance of a single drug is one thing, but when it comes to polypharmacy, getting to the bottom of an adverse event is even more complex. When treatments involve several drugs, often prescribed by different healthcare parties with limited knowledge of a patient’s full history, it can be challenging to determine which drug caused adverse event, or whether interactions between them play a role.

In this issue, we explore the challenges of safety reporting in patients taking more than one drug, and how the process – and patient safety – can be improved.

We also speak to XIL Health founder and CEO Susan Lang about the future potential of 3D-printing in drug manufacturing. We hear why Lang believes 3D printing in drug manufacturing could revolutionise personalised medicine, democratise access to medicines, improve sustainability in the supply chain and speed up the response time when infectious diseases spread.

Elsewhere in this issue, we find out how the narrow FDA panel vote on Merck’s molnupiravir could bolsters the outlook on mAbs, explore the potential of value-based pricing plans for therapies that become available after an FDA accelerated approval, and explore whether drug repurposing could uncover better treatments for UTIs.

Read the latest issue of Pharma Technology Focus  for all this and more new, insights, data and analysis from the pharmaceutical industry.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

You can also subscribe here to receive email notifications when a new issue is available.